Clinical Trials Browser

OTHER_GOV × Carcinoma, Non-Small-Cell Lung × Docetaxel × Clear all

NCT07050043 2025-07-03

LEDANG

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05878028 2024-05-23

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01356368 2014-01-22

Customizing

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01442909 2011-09-29

Pemetrexed Followed by Docetaxel or in Reverse Sequence

Phase 4 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms